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Abstract:- 
Psoriasis is a skin disease that is characterized by a chronic relapsing nature, although the clinical diagnosis of 
psoriasis is easy to make , it is hard to manage satisfactorily. dysregulated angiogenesis has been detected in 
inflammatory diseases and might be a cause of chronic cutaneous inflammation in psoriasis. 
Narrowband ultraviolet B (NB-UVB) phototherapy is a first option treatment for severe psoriasis due to its 
efficacy and safety. It applied either as monotherapy or in combination with topical ointments, oral retinoids 
and/or biologic agents. 
The objective of the study to evaluate the efficacy and impact of psoriasis  treatment (narrowband UVB 
phototherapy and/or topical treatment) on serum concentrations of VEGF and its soluble receptors(VEGFR1 and 
VEGFR2)  and compare post treatment levels of these parameters with the controls. 
One hundred consenting psoriatic patients (males and females) aged 20-60 years who attended different medical 
centers including Al-Sadr Medical City and department of laser research in AL-Najaf city and Marjan Medical 
City in AL-Hilla -Iraq. Psoriasis area and severity index assessment was done for each patient. Blood samples 
was collected for vascular endothelial growth factor and its receptors (1&2 ) measurement. 
Psoriasis is chronic disease as the majority of the patients had disease duration of more than two years. Serum 
VEGF, sVEGFR1 and sVEGFR2 are important in the pathogenesis of psoriasis, as their level are significantly 
elevated in severe form of psoriasis and both topical treatment and NB-UVB are effective in the management of 
psoriatic patients. 
Keywords: Serum vascular endothelial growth factor, serum vascular endothelial growth factor receptor 1, 
Serum vascular endothelial growth receptor 2,Psoriasis area and severity index,  Psoriasis, NBUVB. 
List of abbreviation: sVEGFR= serum vascular endothelial growth factor receptor, PASI = Psoriasis area and 
severity index, SD=standard deviation , ECs=endothelial cells. ELISA= Enzyme Linked Immuno Linked 
Sorbant Assay. NB-UVB=narrow band ultra violet phototherapy. 
 
Introduction 
Psoriasis is a common, inflammatory, chronic and noncontagious skin disease, Although the precise cause of 
psoriasis is ambiguous, psoriasis may be the consequence of two main mechanisms: a polygenic inheritance that 
comprises 36 chromosomal susceptibility loci, and the other, a strong immunological component[1]. New 
researches have been identified that the hyperproliferation and altered differentiations of keratinocytes that 
occurred in psoriasis may link the pathways of angiogenesis and inflammation. Vessels expansion looks to show 
a significant role in the development of psoriatic plaques [2]. 
Vascular endothelial growth factor is a chief factor of neoangiogenesis [3]. The influence of VEGF is 
intermediated by VEGF receptors (VEGFRs, comprising VEGFR-1,VEGFR-2 which are principally expresses 
by vascular endothelial cells (ECs). Vascular endothelial growth factor attaching one of the receptor results in 
receptors stimulation and intracellular signals transductions [4]. There are inadequate information about the 
probable role of soluble VEGF receptors in psoriasis [5]. 
The psoriatic lesion is distinguished by sharply marginated erythematous plaque with a white silvery 
scale that spread in a roughly symmetrical fashion on the trunk and limbs [6]. 
When scales are entirely scrapped off, the basement membrane is exposed and perceived as a red moist 
surface (Membrane of Bulkeley), through which dilated capillaries are noticed as red spots. Characteristically, 
the amplified vascularization could be confirmed clinically, by “Auspitz sign” wherever rubbing scales of 
psoriatic plaque result in pinpoint bleedings. On the other hand, Auspitz sign is not sensitive or specific for 
psoriasis [7]. 
Narrowband ultraviolet B (NB-UVB) phototherapy is a first option treatment for severe psoriasis due to 
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its efficacy and safety. It applied either as monotherapy or in combination with topical ointments, oral retinoids 
and/or biologic agents[8]. Vascular endothelial growth factor (VEGF) is recognized as a pivotal factor 
responsible for angiogenesis in different tissues. Overexpression of VEGF can upregulate angiogenesis in 
psoriatic skin if it dominates the activity of antiangiogenic factors and account for the chronicity in psoriatic 
lesion [9 ,10] 
The objective of the study to evaluate The efficacy and impact of psoriasis  treatment (narrowband UVB 
phototherapy and/or topical treatment) on serum concentrations of VEGF and its soluble receptors(VEGFR1 and 
VEGFR2)  and compare post treatment levels of these parameters with the controls. 
 
Materials and Methods 
This is a case-control study which included 150 subjects (100 patients and 50 controls) who attended different 
medical centers including Al-Sadr Medical City and department of laser research in AL-Najaf city and Marjan 
Medical City in AL-Hilla city from November/2013 to January /2015. Informed consents were gained from 
participant. The practical's parts of this study were done at the Biology Department  / College of Science 
/Babylon University. 
The inclusion criteria include, consenting, patients having chronic plaque psoriasis with PASI score > 
20 aged between 20 to 60 years with no co morbid illness or any medications. 
After informed written consent, Psoriasis Area Severity Index (PASI) scoring was estimated [11]. 
 
The groups of the patients are as the following 
1- Group I: Includes 20 males whose age ranged from 20 to 39 years old and they are divided into two 
subgroups according to type of treatment:- 
A- Includes 10 males on topical treatment . 
B- Includes 10 male on topical treatment and phototherapy . 
2- Group II: Includes 33 females whose age ranged from 20 to 39 years old and they are divided into two 
subgroups according to type of treatment:- 
A- Includes 16 females on topical treatment.  
B- Includes 17 female on topical treatment and phototherapy. 
3- Group III: : Includes 23 males whose age ranged from 40 to 60 years old and they are divided into two 
subgroups according to type of treatment:- 
A- Includes 11 males on topical treatment . 
B- Includes 12 male on topical treatment and phototherapy . 
4- Group IV: Includes 24 females whose age ranged from 40 to 60 years old and they are divided into two 
subgroups according to type of treatment:- 
A- Includes 13 females on topical treatment . 
B-    Includes 11 female on topical treatment and phototherapy . 
Once taking informed consent and the history from the patients which includes age, gender, smoking 
history, disease duration and duration of present relapse, patients were exposed to whole body narrowband 
UVB radiation chamber. 
sVEGF, sVEGFR1 and sVEGFR2 measurements: Eight to ten milliliters of blood were collected in plane 
tube without anticoagulants , the tubes were left for 30 minute at room temperatures. After coagulation, tubes 
were centrifuge at 1000 xg for about 15 minutes, the serum  was extracted and allocated into three parts ,and 
kept at (–20 C) till usage time. Serum aliquots were obtained to measure sVEGF, sVEGFR1 and sVEGFR2 
before and after treatment with NB UVB phototherapy and / or topical treatment by sensitive Enzyme Linked 
Immuno Linked Sorbant Assay technique (ELISA) using ABCAM  Human sVEGFR1 and sVEGFR2 ELISA 
Kits [12]. 
 
Statistical Analysis 
Statisticalcanalysis were done by SPSS 20.0 (SPSS Inc, Chicago, I L, U S A). 
The normal distribution was confirmed for all analyzed measures. For correlation analysis, independent t-test  
was used to estimate differences between two groups in continuous variables as well as the paired t-test was used 
to estimate the difference between the pre and post treatment levels of the measured parameters. the Pearson's 
product moment correlation was used. Results are reported as mean and standard deviation (mean ±SD) unless 
otherwise indicated. P<0.05, was considered statistically significant , P<0.01, was considered highly significant 
and P<0.001, was considered extremely significant [13]. 
 
Results 
Of 100 patients included in the study ,43(43%) males and 57 (57%) females. The males to females ratio was 
1:1.3.  The mean duration of psoriasis was12.80± 12.45years (1month - 40 years) (table 1).  About 89 % of the 
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patients had disease duration for more than 2 years. 
The patients presented severe form of disease as revealed by psoriasis areas and severity index (PASI) 
score (mean ±SD) of 35.85 ± 9.45 with range (20.76-51.97). 
It was found that there was significant improvement in skin lesions (P<0.05) signified by reduction in 
PASI score in group A patients (on topical treatment alone) and significant improvement in skin lesions (P<0.01) 
for group B patients (on NB UVB phototherapy plus topical treatment) and there was significant difference 
between the two groups(P<0.05) (table 1). This means that patients on combined therapy responded better and 
had more reduction in PASI score than patients treated with topical treatment alone. 
Table 1 : Psoriasis area and severity index(PASI) score (Mean ±SD) for both treatment groups before and 
after treatment. 
Treatments groups PASI score Before 
treatment (Mean ±SD) 
PASI score              After 
treatment (Mean ±SD) 
 
P value 
Group A (Patients on 
topical treatment) 
 33.145± 9.124 15.225± 6.483 0.0162*  
0.046* 
Group B (Patients on NB 
UVB phototherapy plus 
topical treatment) 
37.812± 10.82 7.172± 8.767 0.004** 
PASI : psoriasis area and severity index;*Significant difference between groups (P < 0.05);**Highly significant 
difference between groups (P < 0.01). 
The serum level of vascular endothelial growth factor (VEGF) concentrations was significantly higher 
in both treatments groups and for all age groups of psoriatic patients when compared with the healthy controls 
(P<0.001). Concerning the serum level of vascular endothelial growth factor receptor 1, VEGFR1 was 
significantly higher in both treatments groups and for all age groups of psoriatic patients when compared with 
controls (P<0.001). About the serum level of vascular endothelial growth factor receptor 2, VEGFR2 statistically 
showed high significant elevation in both treatments groups (A&B) for all age groups of psoriatic patients when 
compared with the healthy controls (P<0.001). (table 2 ; table 3 ;table 4; table 5; table 6; table 7 ; table 8 and 
table 9) . 
Firstly before we  studied the effect of treatment, we compared the baseline serum level of VEGF, 
sVEGFR1 and sVEGFR2 between the two groups (A&B) and we found that there were no significant 
differences between the two groups for all ages groups regarding sVEGF, sVEGFR1 and sVEGFR2 (P>0.05) 
In respect to the effect of treatment, it was found that in comparison to the pretreatment level there was 
highly significant improvement (P<0.01) in serum VEGF for group I (A&B) , group II(A), group III(A&B) and 
group V(B) while there was extremely significant improvement (P<0.001) for group II (B)and significant 
improvement (P<0.05) for group IV(A). However when we compared the post treatment level of VEGF in 
psoriatic patients with the controls there was still extremely significant elevation(P<0.001) for group IV(A) 
while highly significant elevation (P<0.01) in serum VEGF for group I (A&B) , group II (A), group III (A&B) 
and group IV (B) and there was significant elevation (P<0.05) for group II (B). 
Similarly, it was noticed that there was there was extremely significant improvement (P<0.001) for 
group II(B) while highly significant improvement in VEGF R1 (P<0.01) compared to the baseline level for 
group I (A&B) , group II(A), group III(A&B) and group V(B) and significant improvement (P<0.05) for group 
V(A). As well as when we compared the post treatment level of VEGF R1 in psoriatic patients with the control 
there was still extremely significant elevation(P<0.001) for group I(A) , group III (A) and group V (A) as well as 
highly significant elevation (P<0.01) in serum VEGFR1 for group I (B) , group II (A), group III (B) and group V 
(B) while there was significant elevation (P<0.05) for group II (B). 
Regarding VEGF R2, we noticed that there was significant reduction (P<0.05) in serum VEGFR2 for 
group I (A) , group III(A) and group V(B) while there was high significant reduction (P<0.01) for group 
IV(B)and extremely significant reduction (P<0.001) for group I(B) for group II (A&B) and group III (B). 
Likewise, the comparison of the post treatment level of VEGFR2 in psoriatic patients with the healthy 
control showed that there was still significant increase (P<0.05) in serum VEGFR2 for group I (A&B) , group II 
(A), group III (A) and group V (A&B) while there was insignificant elevation (P>0.05) for group II (B) and 
group III (B). 
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Table 2: Mean (±SD) vascular endothelial growth factor (sVEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group IA patients before and after treatment in comparison with controls. 
 VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After  
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patient 682.78± 
206.99 
448.50± 
142.50 
601.18± 
102.63 
359.61± 
93.53 
10956.58± 
2694.18 
8277.54± 
2074.36 
P value                     0.0012**                     0.0045**                         0.037* 
Controls 210.61 ± 22.24 110.33 ± 30.56 7083.66± 1053.98 
P value ***       
0.0001 
**          
0.0032 
***       
0.00012 
***      
0.0004 
**         
0.0023 
*             
0.022 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. *Significant difference between 
groups (P < 0.05); **Highly significant difference between groups (P < 0.01);   ***Extremely significant 
difference between groups (P < 0.001). 
 
Table 3 :Mean(±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group IB patients before and after treatment in comparison with controls. 
 
 
VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 
 
705.96± 
184.89 
335.64± 
137.16 
622.45± 92.43 264.86± 
82.66 
11136.58± 
2699.79 
7743.64± 
1529.56 
P value 0.0013** 0.0001*** 0.0001*** 
Controls 210.61± 22.24 110.33±30.56 7083.66± 1053.98 
P value ***   0.0001 **     0.0021 ***    0.0001 **        0.003 **       0.0019              0.084 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
*Significant difference between groups (P < 0.05); **Highly significant difference between groups (P < 0.01). 
***Extremely significant difference between groups (P < 0.001). 
 
Table 4: Mean (±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group II A patients before and after treatment in comparison with controls. 
 
 
VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 673.95± 
192.54 
464.42± 
229.16 
585.32±    
81.61 
325.92± 
115.52 
11479.55± 
2462.87 
8810.66± 
2981.45 
P value 0.002*** 0.0001*** 0.001*** 
controls 195.76 ± 36.77 122.13± 31.83 7672.90± 1743.12 
P value *** 0.00035 **        
0.0087 
***        
.00014 
**    0.00431 ***     0.00156 *      0.0286 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
*Significant difference between groups (P < 0.05);**Highly significant difference between groups (P < 0.01); 
***Extremely significant difference between groups (P < 0.001). 
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Table 5: Mean (±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group II B patients before and after treatment in comparison with controls. 
 
 
VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 696.29±  
182.81 
316.61± 
113.27 
613.28± 
121.52 
184.32± 
54.91 
10893.36± 
2378.63 
7734.19± 
2290.89 
P value 0.0001*** 0.0001*** 0.0001*** 
controls 195.765 ± 36.77677 122.131± 31.83233 7672.907± 1743.1227 
P value ***  0.00098 *0.013 *** .000298 *        0.023 ***     0.00045              0.943 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2; *Significant difference between 
groups (P < 0.05);**Highly significant difference between groups (P < 0.01); ***Extremely significant 
difference between groups (P < 0.001). 
 
Table 6: Mean (±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group IIIA patients before and after treatment in comparison with control. 
 VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2[pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 664.97± 
198.63 
465.55± 
198.63 
575.56± 
135.82 
407.33± 
102.82 
10287.53± 
3966.17 
8415.30± 
2105.5 
P value 0.0013** 0.021* 0.041* 
controls 184.83 ± 48.68 105.82 ± 15.63 7309.66± 1284.69 
P value ***     0.0001 **        0.001 ***    0.0001 ***     0.0002 *            0.035 *               
0.048 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
*Significant difference between groups (P < 0.05); **Highly significant difference between groups (P < 
0.01);***Extremely significant difference between groups (P < 0.001). 
 
Table7: Mean (±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group IIIB patients before and after treatment in comparison with controls. 
 VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 649.60± 
199.84 
378.22± 
111.53 
597.74± 
117.04 
289.34±    
78.68 
10928.34± 
2615.96 
7541.43± 
2059.16 
P value 0.0032** 0.0001*** 0.0001*** 
controls 184.83±48.68 105.82 ± 15.63 7309.66± 1284.69 
P value *** .0001 **         0.006 ***         0.0009 **       0.003 ***      
0.0002 
                0.761 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
**Highly significant difference between groups (P < 0.01); ***Extremely significant difference between groups 
(P < 0.001). 
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Table 8: Mean (±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group IVA patients before and after treatment in comparison with controls. 
 
 
VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 667.92± 
202.82 
501.90± 
154.47 
558.77± 
101.19 
435.44± 
130.59 
11075.05± 
2495.03 
8807.11± 
1773.40 
P value 0.03* 0.028* 0.005** 
controls 200.53 ± 43.57 116.71 ± 19.59 7646.007± 1592.50 
P value **          0.001 ***  0.00045 ***   0.00065 *** 0.000219 **               
0.001 
*           0.035 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
* Significant difference between groups (P < 0.05); **Highly significant difference between groups (P < 0.01); 
***Extremely significant difference between groups (P < 0.001). 
 
Table 9: Mean (±SD) vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations in serum of group IVB patients before and after treatment in comparison with controls. 
 
 
VEGF [pg ⁄ mL] sVEGF R1 [pg ⁄mL] sVEGF R2 [pg ⁄ mL] 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
Before 
treatment 
After 
treatment 
patients 689.21± 
210.86 
405.22± 
201.76 
589.06± 
133.62 
318.73± 
89.19 
10676.33± 
3702.27 
8365.50± 
2249.20 
P value 0.003** 0.0002*** 0.01* 
controls 200.53 ± 43.57 116.711 ± 19.59 7646.007±1592.50 
P value ***  0.00021 **           
0.005 
***   0.00023 **       0.0061 *              0.027 *        0.0413 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. *Significant difference between 
groups (P < 0.05); **Highly significant difference between groups (P < 0.01); ***Extremely significant 
difference between groups (P < 0.001). 
Baseline serum VEGF concentration increased in accordance with psoriasis activity demonstrated 
through PASI score. Statistically significant correlation was demonstrated between sVEGF serum concentration 
and PASI score while there were no associations between sVEGF levels and patients age, duration of present 
relapse and duration of whole disease (P>0.05).Also both  sVEGF R1 and sVEGF R2 did not demonstrate 
significant association (P>0.05) with analyzed measures including PASI score (Table 10). 
Table 10: Mean values (±SD) of ages, duration of the disease, its present relapse, psoriasis area severity 
index (PASI) and correlation (expressed as r-value) between these measures and serum vascular 
endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 concentrations before start of the treatment 
Parameters    (Mean ±SD) sVEGF sVEGFR1 sVEGFR2 
Ages(years)  
38.33±13.678 
r -.030 -0.16 -0.113 
P 0.091 0.117 0.312 
Disease duration(years)  
12.8075± 12.4579 
r -0.149 0.037 0.187 
P 0.089 0.132 0.58 
Duration of present relapse 
(months) 
 
6.6513±11.45049 
r 0.103 -0.029 0.042 
P 0.756 0.112 0.314 
PASI score  
35.853 ± 9.453 
r 0.784 0.116 0.065 
P     0.022* 0.087 0.176 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
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*Statistically significant (P < 0.05) correlation ;    r correlation coefficient.        
As shown in Table 11, there were no significant difference in sVEGF, sVEGF R1 and sVEGF R2 
concentrations between patients with positive family history of psoriasis and patients with negative family 
history (P>0.05) as well as between smokers and non-smokers (P>0.05). Concerning the sex there were no 
significant changes in serum level of VEGF, VEGFR2 and VEGFR2between males and females in addition 
between patients in age group of 20-39 and in age group of 40-60 (P>0.05) . 
 
Table 11: Mean values (±SD) of serum vascular endothelial growth factor (VEGF), sVEGF R1 and 
sVEGF R2 concentrations according to the family history, smoking history, age and sex before start of the 
treatment. 
Parameter sVEGF     (Mean 
±SD) 
P 
value 
sVEGFR1 
(Mean± 
SD) 
P 
value 
sVEGFR2 
(Mean 
±SD) 
P 
value  
 
Family history 
Positive 649.919± 231.33   
0.087 
589.923± 
132.415 
 
0.668 
1034.345± 
2354.765 
 
0.141 
Negative 696.714± 154.654  611.678± 
123.6234 
9954.376± 
2875.132 
 
Smoking history 
positive 653.5648± 
178.736 
  
0.287 
575.3985± 
123.986 
 
0.498 
10975.234± 
2187.456 
 
0.749 
Negative 694.1985±89.876  583.574± 
98.835 
11136.493± 
2198.9376 
 
Sex 
male 674.3598±191.869   
0.836 
598.6179± 
111.10772 
 
0.667 
10819.412± 
2959.88199 
 
0.676 
female 682.4513± 
190.35818 
 588.9640± 
108.34053 
11059.849± 
2677.854 
 
Age(in years) 
20-39 688.68± 185.687  
0.587 
604.1189± 
99.36877 
 
0.294 
11132.66± 
2465.189 
 
0.499 
40-60 667.5213± 196.5 580.6765± 
119.27579 
10745.96± 
3147.35457 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2.Statistically insignificant difference 
between groups (P > 0.05). 
Additionally sVEGF, sVEGF R1 and sVEGF R2 did not demonstrate significant association (P>0.05) 
with family history, smoking history and sex (Table 12). 
 
Table 12: Family history, smoking history, sex and correlation (expressed as r-value) between these 
measures and serum vascular endothelial growth factor (VEGF), sVEGF R1 and sVEGF R2 
concentrations before start of the treatment. 
Parameters  
 sVEGF sVEGFR1 sVEGFR2 
 
Family history 
r         -0.051   0.151 0.174 
P          0.760   0.364 0.289 
 
Smoking history 
r         -0.119  -0.084 0.050 
P          0.463 0.612 0.759 
 
Sex 
r          0.021 -0.044 0.043 
P    0.836    0.667 0.676 
sVEGF : serum vascular endothelial growth factor ; sVEGFR1: serum vascular endothelial growth factor 
receptor1; sVEGFR2: serum vascular endothelial growth factor receptor2. 
Statistically insignificant difference between groups (P > 0.05). 
In this study, narrow band UVB phototherapy plus topical treatment are used for treatment of psoriatic 
patients, for comparison, topical treatment was utilized as another therapy. With these therapies going on, all 
patients responded well without any uncomfortable complaints. Concerning the changes in the parameters 
studied with combination of NB-UVB plus topical therapies, we found that all parameters improved and that the 
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improvement was higher( more reduction) for the treatment with NB-UVB plus topical treatment than the 
treatment with topical treatment alone. 
Starting with sVEGF,  for group I, there was significant difference (P<0.05) between patients on topical 
treatment and patients on combination of topical treatment plus NB UVB phototherapy . Regarding group III, 
there was highly significant difference (P<0.01) between patients on topical treatment and patients on 
combination of topical treatment plus NB UVB phototherapy(figure 1 ). 
 
Figure 1: Post treatment level of vascular endothelial growth factor for males and females with age 
group of 20-39years (group I & group II). 
sVEGF : serum vascular endothelial growth factor . 
*Significant difference between groups (P < 0.05). 
**Highly significant difference between groups (P < 0.01). 
Concerning group III as well as group IV, there was significant difference (P<0.05) between patients on 
topical treatment and patients on combination of topical treatment plus NB UVB phototherapy (figure  2). 
 
Figure 2: Post treatment level of vascular endothelial growth factor for males and females with age 
group of 40-60years (group III & group IV). 
sVEGF : serum vascular endothelial growth factor . 
*Statistically significant difference between groups (P < 0.05). 
It means that patients on combination treatment of topical plus NB UVB phototherapy responded better 
and there was significant reduction in sVEGF concerning group I, group II and group IV and highly significant 
reduction regarding group III than patients on topical treatment alone. Concerning sVEGFR1, in group I, there 
was significant difference (P<0.05) between patients on topical treatment and patients on topical treatment plus 
NB UVB phototherapy. Regarding group II, there was highly significant difference (P<0.01) between patients on 
topical treatment and patients on topical treatment plus NB UVB phototherapy (figure 3). 
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Figure 3: Post treatment level of vascular endothelial growth factor receptor1 for males and females 
with age group of 20-39years(group I & group II). 
sVEGF : serum vascular endothelial growth factor ;*Significant difference between groups (P < 0.05). 
**Highly significant difference between groups (P < 0.01). 
Regarding group III, there was significant difference (P<0.05) between patients on topical treatment and 
patients on topical treatment plus NB UVB phototherapy. With regard to group IV, there was highly significant 
difference (P<0.01) between patients on topical treatment and patients on topical treatment plus NB UVB 
phototherapy (figure 4). 
 
 
Figure 4: Post treatment level of  vascular endothelial growth factor receptor 1 for males and females 
with age group of 40-60years60years (group III & group IV). 
sVEGF : serum vascular endothelial growth factor ;*Significant difference between groups (P < 0.05). 
**Highly significant difference between groups (P < 0.01). 
Regarding the sVEGFR2 , for group I, there was insignificant difference (P>0.05) between patients on 
topical treatment and patients on topical treatment plus NB UVB phototherapy. Observing group II, there was 
significant difference (P<0.05) between patients on topical treatment and patients on topical treatment plus NB 
UVB photothera 
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Figure 5: Post treatment level of vascular endothelial growth factor receptor2 for males and females with 
age group of 20-39years. 
sVEGF R2: serum vascular endothelial growth factor receptor2 ;*Significant difference between groups (P < 0.05). 
 Regarding group III, there was significant difference (P<0.05) between patients on topical treatment and patients 
on topical treatment plus NB UVB phototherapy whereas there was insignificant difference (P>0.05) between 
patients on topical treatment and patients on topical treatment plus NB UVB phototherapy in group IV psoriatic 
patients(figure 6 ).   
 
Figure 6: Post treatment level of vascular endothelial growth factor receptor 2 for males and females with 
age group of 40-60years. 
sVEGFR2 : serum vascular endothelial growth factor receptor2.  
*Significant difference between groups (P < 0.05). 
 
Discussion 
The mean duration of psoriasis was12.8± 12.45years (1month - 40 years) (table 1).  About 63% of the patients 
had disease duration from 2-10 years. 
In this study maximum (89%) of the patients were found suffering for more than two years duration. 
This indicate that the disease is chronic , tough in nature and resist to treatment. This finding is in accordance 
with the description given by Susan Burge and Dinny wallis[14]. 
Familial clustering in psoriasis had been observed for many years (15). A positive family history in 
55%of the studied sample provided another support of this concept. Moreover, it confirmed the important role of 
genetics in the etiology of psoriasis especially in those with early onset (16).This figure was also in agreement 
with the figure reported few years ago in the same locality (Mosul city) which was 38.5% (17). 
A large-scale observational study conducted in Spain, the authors showed that, as the age of onset of 
psoriasis increased, there was a progressive decrease in the incidence rates of a positive family history of 
psoriasis (16). Their results pointed towards two different psoriasis subtypes: a subtype with a strong genetic 
background for the disease (early onset psoriasis) and one in which genetic factors play a secondary role (late 
onset psoriasis) (18). 
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Association with smoking was seen in 44% of our patients which is consistent with a study of Al-
Rubaiy &Rubiay (19) on Iraqi population and they found that about 40% of the patients are smokers and also 
consistent with  Nisa &Qazi, (20) on indian population and they found that about 42% of the patients were 
smokers. Association with smoking may be partly explained by the action of nicotine in promoting Th1 mediated 
inflammation (21). Smoking induces an overproduction of IL-1β, TNF-α and TGF-β, which have been 
associated with psoriasis severity (22). 
The patients presented severe form of disease as revealed by psoriasis areas and severity index (PASI) 
score (mean ±SD) of 35.85 ± 9.45 with range (20.76-51.97).and regarding the effect of treatment, It was found 
that there was significant improvement in skin lesions signified by reduction in PASI score in all groups of 
psoriatic patient as compared to the baseline values. In the current work, our data confirmed that both NB-UVB 
plus topical treatment and topical treatment alone were able to induce a significant reduction in the PASI score 
after 12 weeks of therapy and the PASI score reduction was more with mixed treatment (topical plus NB UVB 
Phototherapy) than topical treatment alone(table 1). 
As much as we know ,there was no matched study to our study and  Flisiak and his coworkers (23) who 
used only topical treatment evaluated PASI before treatment and he found that PASI varied from 4.2 to 41.2 
(mean 15.8 ± 1.3; median 15.1). After 14 days of topical treatment,  PASI decreased to values between 0 and 4.3 
(mean 1.2 ± 0.2). Another study done by Elghandour and his colleagues (24) and he found that there was 
significant reduction in PASI score for patients treated with narrow band UVB phototherapy alone as well as 
significant reduction for patients treated with methotrexate. 
Our results also are agreed with the results of Zhou his colleagues (25) who used topical treatment and 
for comparison used NB-UVB phototherapy alone and they found that both of the two therapies were effective 
for clinical improvement showed by reduction in PASI score . 
Concerning sVEGF, our  results suggest that there is extremely significant increment in sVEGF in all 
psoriatic patients compared to the controls. 
Our results are compatible with the finding of other several authors who  reported that its levels are 
significantly high in plasma in the active stage of the disease (26,27,28 and29). Nonetheless, Shimauchi and his 
coworkers (2013) did not find significant differences in sVEGF levels between psoriasis patients and controls.  
Flisiak and his coworkers (30) and Flisiak and his co-workers (23) reported that the increment of serum VEGF 
became significant only in patients with medium and severe activity of the disease. 
Dysregulated angiogenesis has been observed in inflammatory diseases and might be underly chronic 
cutaneous inflammation in psoriasis (31). Several experimental studies and clinical reports suggested that VEGF 
was involved in psoriasis pathogenesis, among those, transgenic over-expression of VEGF in keratinocytes in 
mice resulted in skin inflammation and a phenotype resembling human psoriasis. In different psoriasis models, 
anti-VEGF antibody treatment of mice, already displaying disease symptoms, resulted in an overall improvement 
of the cutaneous lesions (31). Additionally, a patient with psoriasis was reported to have complete remission of 
psoriasis during bevacizumab (a monoclonal antibody against VEGF) therapy for colon cancer (27).  Therefore, 
VEGF is a pro-inflammatory factor in the pathogenesis of psoriasis. 
Additional emerging evidence for a role of VEGF in the etiology of psoriasis comes from genetic 
analyses showing an association between VEGF promoter polymorphisms and the development of psoriatic 
symptoms (32). 
Concerning sVEGFR1, our  results suggest that there is extremely significant increment in sVEGFR1 in 
all psoriatic patients compared to control. 
Our result are in agreement with the finding of Flisiak and his co-workers (30) and Flisiak and his co-
workers (23) who reported that the increase of serum VEGFR1 becomes significant only in patients with severe 
psoriasis. 
Young and his co-workers (33) also found significantly enhanced VEGF serum levels as well as 
increased levels of circulating (soluble) VEGFR-1 in psoriasis patients, although no direct correlation with 
disease severity as measured by the PASI score was found in this study . 
Concerning the serum level of vascular endothelial growth factor receptor 2, our  results suggest that 
there is extremely significant increment in sVEGFR2 in all psoriatic patients compared to control. Our finding 
disagrees with Flisiak and his co-workers (30) and Flisiak and his coworkers (23)  who did not find significant 
differences in VEGFR2 levels between psoriatic patients and controls. Up to our knowledge no study till now 
supports our result regarding sVEGFR2 apart from experimental study done by Man et al., (34) and Zhou et al.,  
(25) who measure epidermal VEGFR1 and VEGFR2 and they discovered that vascular endothelial growth factor 
receptors (VEGFR1 and VEGFR2) were found to be over-expressed in psoriatic epidermis compared to controls, 
implicating their pathological significance in the disease. Man et al., (34) demonstrated that the overexpression 
of VEGFR-1/2/3 is in psoriatic epidermis at both mRNA and protein levels. Moreover, VEGFRs were strongly 
labeled in non-lesional, perilesional, and lesional psoriatic keratinocytes in all epidermal stratums in vivo. 
Furthermore, exogenous VEGF and calcium could enhance the expression of VEGFRs. These results provide 
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another prospective to understand the mechanism of VEGF in psoriasis. That is to say, VEGF participates in the 
pathogenesis of psoriasis through two manners. One is that keratinocytes-derived VEGF induces angiogenesis to 
provide essential nutriments, energy, and cells to support the hyperproliferation of epidermis in a paracrine 
manner indirectly; the other one is that VEGF directly stimulates the proliferation of keratinocytes via VEGFRs 
expressed on epidermis in an autocrine manner(34). 
Interestingly enough, hypoxia and oxidative stress also existed in the psoriatic lesions, which might be 
associated with overexpression of VEGFRs and subsequent hyperplasia of the epidermis(35 and 36). 
Results of this study provide rationale for possible application of VEGF, sVEGF R1 and sVEGF R2 
serum measurement as a biomarkers of psoriasis activity and predictor of possible exacerbation. As VEGF and 
its receptors are currently considered as possible targets of future psoriasis therapies, their measurement could 
also be useful in the evaluation of the treatment efficacy (31). 
In addition, researches showed that VEGFRs were also overexpressed in psoriatic epidermis ( 25 and  
34), but their real function in psoriasis remained unclear. Based on the findings that proliferation of keratinocytes 
could be promoted via VEGF/VEGFRs pathway (37 and 38), and that treatment with a VEGFR tyrosine kinase 
inhibitor could inhibit chronic and acute skin inflammation seen in psoriasis (39), and that the overexpressed 
VEGFRs in psoriatic epidermis might be involved in the pathological process of psoriasis (25). 
TNF-α upregulates VEGFR-2 expression and has been shown to stimulate angiogenesis, enhance 
VEGF-mediated endothelial cell migration, and enhance wound healing (40). 
TNF-α levels are elevated in psoriasis and play an important part in T-cell proliferation and disease 
pathogenesis (41). Treatment with the anti-TNF-α agent infliximab improves skin and joint disease and reduces 
VEGF expression in dermal and synovial tissue with corresponding reductions in tissue vascularity (42). 
As shown in Table 10, there were no associations between VEGF levels and patients age, duration of 
present relapse and duration of whole disease (P>0.05). 
Our results are in accordance with the finding of Flisiak and his co-workers (30). Nonetheless these 
findings disagree with the finding of Al-Shobaili (43) who found that the duration of disease showed significant 
positive correlations with VEGF (r=0.35, P<0.01). 
Both  sVEGF R1 and sVEGF R2 did not demonstrate significant association (P>0.05) with the duration 
of psoriasis, its present relapse, psoriasis area severity index (PASI). These findings are in accordance with the 
finding of Flisiak and his co-workers (23). 
In respect to the effect of treatment, we found that in comparison to the pretreatment level of sVEGF, 
we noticed that there was significant improvement in serum level of VEGF in all group of psoriatic patients who 
treated with topical treatment  as well as significant reduction in serum VEGFR1 . 
Flisiak and his co-workers (23) found that the VEGF levels appear to be reduced by 14 days standard 
topical therapy in addition they found that VEGFR1 was significantly decreased after topical treatment only in 
severe  form of psoriasis as well as these results are in accordance with the results of  Zhou et al.,  (25) who 
measured epidermal level of VEGF and VEGFR1 and found that there were significant reduction in these 
parameters after topical treatment. 
Regarding the serum VEGFR2, there was significant reduction in serum VEGFR2 after 12 weeks 
topical treatment, our results are inconsistent with the results of  Flisiak and his co-workers (23) who found that 
the VEGFR2  levels appear to be not changed after standard topical therapy. In contrast this result  are in 
accordance with the results of  Zhou and his co-workers (25) who measured epidermal level VEGFR2 and found 
that there were significant reduction in its level after topical treatment. 
So, by topical treatment, the conditions of lesional inflammation, hypoxia and oxidative stress were 
gradually relieved, which eventually brought about remission of the disease. In the meantime, the expression of 
VEGFRs declined spontaneously. So, we infer that although VEGFRs are not an initial factor, they really act as a 
key intermediate in psoriasis pathogenesis, and treatments targeting VEGFRs would be of potential significance 
for psoriasis. 
Regarding the patients treated with topical treatment plus NB UVB phototherapy there were significant 
reduction in serum VEGF after 12 weeks of treatment, our results are in agreement with results of Andrys and 
his co-workers (44) who found that serum VEGF are significantly decreased after topical plus NB UVB 
phototherapy treatment. 
Coimbra and his co-workers (28) confirmed that the levels of serum VEGF were significantly decrease 
in psoriatic patients after treatment with NB-UVB phototherapy alone. Nonetheless our findings disagree with 
the results of  Akman and his co-workers (27) who found that the levels of serum VEGF were significantly 
increased in the groups of NB-UVB and Re-PUVA (P<0.001). 
Phototherapy exerts anti-angiogenic effects. In vitro, it reduces endothelial cells proliferation and 
promotes apoptosis (Deng et al., 2004). Whether these effects also apply in vivo is unclear. However, it was 
observed in patients that PUVA and narrowband ultraviolet B (nbUVB) therapy reduced circulating level of 
VEGF (28). 
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Regarding serum VEGFR1 and serum VEGFR2 , There were significant reduction in serum 
concentration of both receptors. And up to our knowledge there were no study compatible to our study apart 
from study of Zhou and his co-workers (25) who measured epidermal level of VEGFR1 and VEGFR2 and found 
that there were significant reduction in their level after NB UVB phototherapy alone. 
VEGFRs may be involved in the pathological process of psoriasis, and NB-UVB phototherapy is 
effective for psoriasis by directly down-regulating the overexpressed VEGFRs in psoriatic epidermis. 
We propose that NB UVB phototherapy cause inhibition of IL-23, as well as TNFα, from DCs, which 
cause inactivation and proliferation of Th17 cells. Subsequently inhibition of IL-22 and IL-17, this lead to 
reverse keratinocyte hyperplasia and subsequent production of VEGF and its receptors contributing to inhibition 
of angiogenesis, characteristic of psoriasis lesions (34). 
However when we compared the post treatment level of VEGF in psoriatic patients with the control 
there was still significant elevation in serum VEGF for patients treated with both treatment modalities. 
These results are in agreement with the results of Coimbra et al ., (28) who found that VEGF was still 
significantly higher than the control in patients treated with NB-UVB irradiation as well as in accordance with 
the results of Flisiak and his co-workers (23) who found that the VEGF levels was still significantly higher than 
the control in patients treated with standard topical therapy. 
Regarding the VEGF receptors ( VEGFR1 and VEGFR2) when we compared the post treatment level 
of both receptors in psoriatic patients with the control there was still significant elevation in serum level of both 
receptors for patients treated with both treatment modalities. 
As far as we know, there were no study compatible to our results. 
NB-UVB irradiation is known to upregulate VEGF and its receptors (45).  However, similar results 
were found for patients treated with topical treatment alone. Sustained high levels of VEGF, even at remission, 
as defined by PASI score, suggest that VEGF might be important in defining the time of remission, as VEGF is 
known to promote vascular permeability that enhances leucocyte traffic into the skin and alters the dermal 
capillaries to express leucocyte chemoattractant molecules (46). Moreover, in addition  that a residual 
inflammation persists after treatment with topical treatment and NB-UVB, as CRP was still higher than the 
control (28). We wonder if this residual inflammatory stimulus, along with higher levels of VEGF and its 
receptors, could favour infiltration of inflammatory cells into the skin and, therefore, the development of lesions. 
As shown in Table 11, there was no significant difference in sVEGF, sVEGF R1 and sVEGF R2 
concentrations between patients with positive family history of psoriasis and patients with negative family 
history (P>0.05) as well as between smokers and non-smokers (P>0.05). 
Up to our knowledge, there is  no study compatible to our study and our explanation is that the psoriasis 
is a polygenic inheritance that comprises 36 chromosomal susceptibility loci (1). although some researcher 
identified that there was "angiogenetic constitution’’ which could determine psoriasis susceptibility based on the 
analysis of single nucleotide polymorphisms of the VEGF gene in  psoriatic and healthy individuals (33). 
Regarding the smoking there was no significant difference between smokers and non-smokers (P>0.05). 
Also there was no compatible research with our finding and this result that the smoking not induce the 
production of VEGF, VEGFR1 and VEGFR2. 
One research demonstrated that smoking induces an overproduction of IL-1β, TNF-α and TGF-β which 
have been associated with psoriasis severity and TGF-β is involved in neovascularization (22). This means that 
smoking affects neovascularization but not through the pathway of VEGF and its receptors. 
Concerning the sex and age, there are no significant changes in serum level of VEGF, VEGFR2 and 
VEGFR2 between males and females along with between patients in age group20-39 and patients in age group 
40-60 (P>0.05) (Table 11) , these results are in accordance with the results of Flisiak and his coworkers (30) and 
with the finding of Flisiak and his coworkers (23) . This findings mean that the level of VEGF and its receptors 
don't affected with age as well as with the sex of the patients. Nonetheless our finding disagrees with the finding 
of  Creamer his coworkers (47) who said that high plasma levels of VEGF-A are associated with early onset 
psoriasis (onset before the age of 40 years) and psoriatic arthritis 
We found that all parameters improved and that the improvement was higher for the treatment with NB-
UVB plus topical treatment than the treatment with topical treatment alone. 
There were significant difference in serum VEGF, sVEGFR1 and sVEGFR2 between patients treated 
with topical treatment alone and patients treated with  topical plus NB UVB phototherapy and this means that 
combined  treatment of topical plus NB UVB phototherapy was more effective in reduction serum VEGF, 
sVEGFR1 and sVEGFR2 than treatment with topical treatment alone. To the extent that we know there was no 
study compatible to our results. The extra effect is attributed to the effect of NB UVB phototherapy on reduction 
of serum VEGF and its receptors in addition to the effect of topical treatment. 
 
Conclusion 
Psoriasis is chronic disease as the majority of the patients had disease duration of more than two years. Serum 
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VEGF, sVEGFR1 and sVEGFR2 are important in the pathogenesis of psoriasis, as their level are significantly 
elevated in severe form of psoriasis and both topical treatment and NB-UVB are effective in the management of 
psoriatic patients. 
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